Rate this item
(1 Vote)

Dr. Michael Har-Noy

By Super User 24 November, 2015 9461

Founder, CEO and Chief Science Officer. Dr. Har-Noy is the founder and inventor of the Mirror Effect technology and serves as the CEO and Chief Science Officer of the parent Immunovative Therapies, Ltd., as well as the President of Immunovative Clinical Research, Inc, the wholly-owned Clinical Research Organization of Immunovative located to Phoenix, AZ USA. Dr. Har-Noy also serves as a consultant to the Center of Excellence for Cancer Treatment and Immunotherapy Research at the Department of Bone Marrow Transplantation and Cancer Immunotherapy at Hadassah-Hebrew University Medical Center in Jerusalem.  Early in his career, he received the National Beta Beta Beta research society first place award for undergraduate research for developing a bioreactor device which was able to maintain rat ovaries alive and cycling outside the body. As a MD-PhD student at Rush University Medical School/Loyola University he developed the first commercial scale hollow-fiver bioreactor for the production of monoclonal antibodies and other mammalian cell-derived products.  Dr. Har-Noy previously developed an autologous Th1 cell therapy for advanced cancer. While a Research Fellow at Harvard Medical School, Department of Immunology, he developed a CD4 viral-purged autologous therapy for HIV.  Dr. Har-Noy brings over 30 years’ experience in translational research in immunology and bioengineering, including pre-clinical development, manufacturing and clinical trials/regulatory affairs.

Last modified on Sunday, 29 January 2017 07:31



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more